Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
72.98
+0.93 (1.29%)
At close: Apr 3, 2025, 4:00 PM
72.16
-0.82 (-1.12%)
Pre-market: Apr 4, 2025, 4:24 AM EDT
Edwards Lifesciences Employees
Edwards Lifesciences had 15,800 employees as of December 31, 2024. The number of employees decreased by 4,000 or -20.20% compared to the previous year.
Employees
15,800
Change (1Y)
-4,000
Growth (1Y)
-20.20%
Revenue / Employee
$344,272
Profits / Employee
$264,215
Market Cap
42.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,800 | -4,000 | -20.20% |
Dec 31, 2023 | 19,800 | 2,500 | 14.45% |
Dec 31, 2022 | 17,300 | 1,600 | 10.19% |
Dec 31, 2021 | 15,700 | 800 | 5.37% |
Dec 31, 2020 | 14,900 | 1,000 | 7.19% |
Dec 31, 2019 | 13,900 | 1,100 | 8.59% |
Dec 31, 2018 | 12,800 | 600 | 4.92% |
Dec 31, 2017 | 12,200 | 1,100 | 9.91% |
Dec 31, 2016 | 11,100 | 1,300 | 13.27% |
Dec 31, 2015 | 9,800 | 700 | 7.69% |
Dec 31, 2014 | 9,100 | 500 | 5.81% |
Dec 31, 2013 | 8,600 | 400 | 4.88% |
Dec 31, 2012 | 8,200 | 400 | 5.13% |
Dec 31, 2011 | 7,800 | 800 | 11.43% |
Dec 31, 2010 | 7,000 | 600 | 9.38% |
Dec 31, 2009 | 6,400 | 200 | 3.23% |
Dec 31, 2008 | 6,200 | 600 | 10.71% |
Dec 31, 2007 | 5,600 | 50 | 0.90% |
Dec 31, 2006 | 5,550 | 150 | 2.78% |
Dec 31, 2005 | 5,400 | 200 | 3.85% |
Dec 31, 2004 | 5,200 | 200 | 4.00% |
Dec 31, 2003 | 5,000 | 0 | - |
Dec 31, 2002 | 5,000 | 189 | 3.93% |
Dec 31, 2001 | 4,811 | -289 | -5.67% |
Dec 31, 2000 | 5,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EW News
- 3 days ago - New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients - Business Wire
- 12 days ago - Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
- 4 weeks ago - Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor - Business Wire
- 5 weeks ago - Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 7 weeks ago - Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength - Benzinga
- 7 weeks ago - Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Edwards Lifesciences beats profit estimate on strength in heart devices - Reuters
- 7 weeks ago - Edwards Lifesciences Reports Fourth Quarter Results - Business Wire